Publications

Filters (8)
October 23, 2018

SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer

Read more
April 17, 2018

The inhibitor of apoptosis protein (IAP) antagonist Debio 1143 enhances the immune response to anti-PD1/L1 inhibitors in vitro and in…

Read more
December 1, 2016

Chemosensitization to Carboplatin and Paclitaxel by IAP Inhibitor Debio 1143 in Ovarian Cancer Cell Lines: Signature Identification for Potential Patient…

Read more
October 29, 2016

Paclitaxel-Carboplatin With The Oral Iap Inhibitor Debio1143 In A Subset Of Patients With Recurrent Epithelial Ovarian Cancer (EOC): Phase I

Read more
June 21, 2016

Population pharmacokinetic analysis of the IAPs antagonist Debio 1143 and its major metabolite in oncologic patients

Read more
April 30, 2016

Phase 1 Study of Debio 1143 with Concurrent Chemo-Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Read more
November 8, 2015

Clinical Safety, Pharmacokinetics and Early Evidence of Activity of The Oral IAPs Inhibitor Debio 1143 in Combination with Carboplatin and…

Read more
October 23, 2015

SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells

Read more
September 21, 2015

The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNF-alpha-mediated in head and neck squamous cell carcinoma.

Read more